Notícias

Honeywell was added to the Dow for its tech focus and diversification across different end markets.

Novavax delivered first quarter results that surpassed Wall Street’s revenue and earnings estimates, leading to a significant positive market reaction. Management attributed the quarter’s performance to strong partner-driven revenue streams, particularly from milestone payments and supply sales tied to agreements with Sanofi and Pfizer. CEO John Jacobs emphasized the shift from direct commercial activity to a strategy anchored by licensing and collaboration, noting, “We now have either licensing

With an annual dividend yield of 6.68%, Pfizer Inc. (NYSE:PFE) is included among the 10 Best Dividend Stocks with 5%+ Yields and Growing Cash Flows. On May 14, Wolfe Research analyst Alexandria Hammond raised the firm’s price recommendation on Pfizer Inc. (NYSE:PFE) to $26 from $25. It reiterated an Underperform rating on the shares following what the […]

The Pacer US Cash Cows 100 ETF (NYSEARCA:COWZ) and the Fundstrat Granny Shots US Large Cap ETF (NYSEARCA:GRNY) sit on opposite ends of how quality gets defined in a large-cap portfolio. COWZ ranks the Russell 1000 by free cash flow yield and takes the top 100 names, a rules-based screen with no human override. GRNY ... GRNY Beat COWZ by 11 Points This Year. Oil Prices and Interest Rates Will Decide Who Wins Next

Pfizer (NYSE:PFE) received European Commission approval to expand HYMPAVZI to adolescents with hemophilia A or B and inhibitors. The decision opens access to a new patient group within the EU hemophilia market for this rare disease therapy. The expanded label highlights bleed protection and a simplified administration regimen for a hard to treat population. For investors watching NYSE:PFE, this update is part of Pfizer's broader push in rare diseases, an area where specialized treatments...

Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) stock is trading higher on Tuesday as the company is entering an exclusive global licensing agreement with Arvinas Inc. (NASDAQ:ARVN) and Pfizer Inc. (NYSE:PFE) for its oral PROTAC drug, VEPPANU (vepdegestrant). This news comes as the...

BioNTech (NASDAQ:BNTX) used its virtual annual general meeting to outline a transition year marked by leadership changes, continued investment in oncology, a planned share repurchase program and a restructuring of its manufacturing network. Chairman of the Supervisory Board Helmut Jeggle said the 2

Corcept raises 2026 revenue guidance after strong Korlym Q1 performance. New launches and pipeline progress may diversify future growth.

Pfizer (NYSE:PFE) at $25.75, Molina Healthcare (NYSE:MOH) at $186.80, and Halliburton (NYSE:HAL) at $41.29 trade at defensive, cash-generative valuations. Michael Burry purchased these shares for their real earnings and margin stability, and with inflation still pressuring margins across the market, names that generate cash, hold pricing power, and trade at sober multiples carry a structural ... Michael Burry’s Latest Buys Include a 6.66% Yielding Pharma Giant and an Oil Stock Up 46% This Year.

Healthcare is booming, and these three companies stand to profit handsomely from growing demand for medications and surgeries.

Pfizer’s first quarter results reflected continued momentum in its core portfolio, with management attributing growth to strong performance in recently launched and acquired products, particularly in oncology and migraine therapies. CEO Albert Bourla credited a 22% increase in revenues from new products and acquisitions, highlighting the success of the Seagen integration and robust demand for Nurtec. Management also pointed to positive developments in legal settlements, which have improved clari

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is one of the 10 Best Aggressive Growth Stocks to Buy According to Wall Street Analysts. On May 5, H.C. Wainwright reaffirmed its Buy rating on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) with a price target of $510 on the stock. This update came after the company reported Q1 results. The company reported […]

Almost half of S&P 500 stocks are down for the year, but a bunch show signs they are reviving. Our screen spotlights the most promising.

Pfizer Inc. (NYSE:PFE) was one of the stocks on which Jim Cramer shared his take, explaining that dot-com analogies do not hold up in this market. A caller inquired if they should hold, sell, or buy more. In response, Cramer said: Pfizer does not have any earnings momentum. You’re just buying it on that dividend […]

The pharmaceutical powerhouse still faces plenty of patent challenges, but it got a big one out of the way, securing time and money to work on other profit centers.

Biotech dealmaking accelerated heading into the JPM 2026 Healthcare Conference as large drugmakers face looming patent cliffs and hunt for growth. Five therapeutic categories are absorbing most strategic capital: radiopharmaceuticals, next-gen GLP-1, autologous CAR-T, allogeneic cell therapy, and antibody-drug conjugates. Below are the publicly traded category leaders in each. Each is a well-positioned standalone business ... Big Pharma’s 5 Hottest Biotech Hunting Grounds: Meet the Category Lead

Pfizer stock slipped after Q1 results despite an earnings beat as investors weighed falling COVID sales and looming patent expirations.

Meta ramps AI infrastructure spending as upgraded recommendations and advertiser tools boost engagement and ad efficiency.

Rigel Pharmaceuticals has entered an exclusive global license agreement with Arvinas and Pfizer to develop, manufacture and commercialize VEPPANU (vepdegestrant), the first FDA-approved oral PROTAC for adults with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer, which was approved in May 2026 following positive Phase 3 VERITAC-2 data. A key nuance is that Rigel assumes worldwide commercialization rights, including the option to sublicense outside the U.S., while Arvinas and...

Moby summary of Protalix BioTherapeutics, Inc.'s Q1 2026 earnings call

Meta ramps up AI infrastructure and ad tools as Pfizer rebounds and Salesforce expands AI offerings amid macro pressures.

Valneva (NASDAQ:VALN) reported lower first-quarter revenue and a wider loss for 2026, while management said the company is focused on conserving cash as it awaits the next regulatory steps for its Lyme disease vaccine candidate being developed with Pfizer. Chief Executive Officer Thomas Lingelbach

Arvinas Inc (NASDAQ:ARVN) reported downbeat results for the first quarter on Tuesday. The company posted quarterly losses of 90 cents per share which missed the analyst consensus estimate of losses of 87 cents per share. The company reported quarterly sales of $15.600 million which missed the analyst consensus estimate of $18.097 million. Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) announced that it is entering an exclusive global licensing agreement with Arvinas and Pfizer Inc. (NYSE:PFE) for its

On Wednesday, Valneva (NASDAQ:VALN) discussed first-quarter financial results during its earnings call. The full transcript is provided below. This transcript is brought to you by Benzinga APIs. For real-time access to our entire catalog, please visit https://www.benzinga.com/apis/ for a consultation. The full earnings call is available at https://edge.media-server.com/mmc/p/xbkzgkz7 Summary Valneva SE reported first-quarter revenues of approximately €30 million, with a decline from the previous

PFE targets high single-digit revenue CAGR from 2029 as new launches, acquisitions and pipeline growth may offset LOE headwinds.

These stocks are facing some headwinds, but they may prove to be big winners in the long run.

Pfizer (NYSE:PFE) and Arvinas have transferred global development and commercialization rights for VEPPANU (vepdegestrant) to Rigel Pharmaceuticals. VEPPANU is the first FDA approved PROTAC therapy and was recently cleared in the U.S. for certain patients with advanced breast cancer. The global license agreement makes Rigel the commercial leader for VEPPANU, while Pfizer and Arvinas retain an economic interest through the deal structure. For investors watching NYSE:PFE, this move highlights...

It's a great time to "buy low."

JNJ bets on Tremfya and newly approved Icotyde to drive immunology growth as Stelara faces biosimilar pressure.

The Dow Jones Industrial Average would be even higher if it had more exposure to energy stocks.